Advertisement
Screener

GSK plc (GLAXF) Form 6-K: Report of foreign private issuer, 2022

2.1 / 5 stars · 17/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2022-12-22: Form 6-K; Period of report 2022-12-22; Description DIRECTOR/PDMR SHAREHOLDING; Document a6662k.htm.
  • 2022-12-21: Form 6-K; Period of report 2022-12-21; Description DIRECTOR/PDMR SHAREHOLDING; Document a5224k.htm.
  • 2022-12-21: Form 6-K; Period of report 2022-12-21; Description DIRECTOR/PDMR SHAREHOLDING; Document a5216k.htm.
  • 2022-12-15: Form 6-K; Period of report 2022-12-15; Description BOARD AND COMMITTEE CHANGES; Document a8923j.htm.
FiledFormPeriod of reportDescriptionDocument
2022-12-226-K2022-12-22DIRECTOR/PDMR SHAREHOLDINGa6662k.htm
2022-12-216-K2022-12-21DIRECTOR/PDMR SHAREHOLDINGa5224k.htm
2022-12-216-K2022-12-21DIRECTOR/PDMR SHAREHOLDINGa5216k.htm
2022-12-156-K2022-12-15BOARD AND COMMITTEE CHANGESa8923j.htm
2022-12-136-K2022-12-13DIRECTOR/PDMR SHAREHOLDINGa5456j.htm
2022-12-076-K2022-12-07STATEMENT: ZANTAC (RANITIDINE) LITIGATIONa8802i.htm
2022-12-056-K2022-12-05TRANSFER OF TREASURY SHARESa5127i.htm
2022-12-026-K2022-12-02DIRECTOR/PDMR SHAREHOLDINGa4893i.htm
2022-12-026-K2022-12-02JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCERa3599i.htm
2022-12-026-K2022-12-02EMA FILE ACCEPTED FOR MOMELOTINIBa3597i.htm
2022-12-016-K2022-12-01TOTAL VOTING RIGHTSa3058i.htm
2022-11-256-K2022-11-25GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATESa5149h.htm
2022-11-226-K2022-11-22BLENREP US UPDATEa1375h.htm
2022-11-216-K2022-11-21DIRECTOR/PDMR SHAREHOLDINGa1074h.htm
2022-11-156-K2022-11-15BLOCK LISTING INTERIM REVIEWa4283g.htm
2022-11-146-K2022-11-14GSK UPDATE: ZEJULA 2L IN USa0676g.htm
2022-11-106-K2022-11-10SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EUa0593g.htm
2022-11-106-K2022-11-10DIRECTOR/PDMR SHAREHOLDINGa0366g.htm
2022-11-106-K2022-11-10BLOCK LISTING APPLICATIONa9172f.htm
2022-11-076-K2022-11-07DREAMM-3 PHASE III TRIAL FOR BLENREPa4558f.htm
2022-11-036-K2022-11-03IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOPa1978f-1.htm
2022-11-026-K2022-11-023RD QUARTER RESULTSa9931e-46147302.htm
2022-11-026-K2022-11-02GSK RSV VACCINE: US FDA PRIORITY REVIEWa9962e.htm
2022-11-016-K2022-11-01TOTAL VOTING RIGHTSa9272e.htm
2022-10-286-K2022-10-28EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEWa4239e.htm
2022-10-286-K2022-10-28EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREPa4238e.htm
2022-10-276-K2022-10-27GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTATa2670e.htm
2022-10-276-K2022-10-27CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATEa2603e.htm
2022-10-256-K2022-10-25BOARD COMMITTEE CHANGESa0214e.htm
2022-10-216-K2022-10-21RSV OLDER ADULT VACCINE SUBMISSION IN JAPANa6404d.htm
2022-10-176-K2022-10-17MENVEO NEW SINGLE-VIAL APPROVED BY US FDAa0229d.htm
2022-10-146-K2022-10-14DIRECTOR/PDMR SHAREHOLDINGa9889c.htm
2022-10-136-K2022-10-13DIRECTOR/PDMR SHAREHOLDINGa8302c.htm
2022-10-136-K2022-10-13DIRECTOR/PDMR SHAREHOLDINGa7994c.htm
2022-10-136-K2022-10-13DIRECTOR/PDMR SHAREHOLDINGa7866c.htm
2022-10-136-K2022-10-13EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINEa7703c.htm
2022-10-126-K2022-10-12DIRECTOR/PDMR SHAREHOLDINGa6690c.htm
2022-10-116-K2022-10-11US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATIONa2615c.htm
2022-10-076-K2022-10-07DIRECTOR/PDMR SHAREHOLDINGa2352c.htm
2022-10-076-K2022-10-07DIRECTOR/PDMR SHAREHOLDINGa2319c.htm
2022-10-036-K2022-10-03TOTAL VOTING RIGHTSa5456b.htm
2022-09-306-K2022-09-30DIRECTOR/PDMR SHAREHOLDINGa4309b.htm
2022-09-266-K2022-09-26DIRECTOR/PDMR SHAREHOLDINGa6963a.htm
2022-09-266-K2022-09-26GSK CHIEF FINANCIAL OFFICER SUCCESSIONa5418a.htm
2022-09-226-K2022-09-22US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIALa3468a.htm
2022-09-226-K2022-09-22GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEMa2350a.htm
2022-09-216-K2022-09-21DIRECTOR/PDMR SHAREHOLDINGa1639a.htm
2022-09-136-K2022-09-13DIRECTOR/PDMR SHAREHOLDINGa2586z.htm
2022-09-086-K2022-09-08DIRECTOR/PDMR SHAREHOLDINGa8109y.htm
2022-09-066-K2022-09-06GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTATa4701y.htm
2022-09-016-K2022-09-01TOTAL VOTING RIGHTSa9678x.htm
2022-08-246-K2022-08-24GSK BOARD CHANGESa9898w.htm
2022-08-226-K2022-08-22DIRECTOR/PDMR SHAREHOLDINGa8265w.htm
2022-08-176-K2022-08-17FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMBa2425w.htm
2022-08-176-K2022-08-17STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATEa2399w.htm
2022-08-166-K2022-08-16GSK COMPLETES ACQUISITION OF AFFINIVAX, INC.a1486w.htm
2022-08-126-K2022-08-12STATEMENT: ZANTAC (RANITIDINE) LITIGATIONa7869v.htm
2022-08-116-K2022-08-11DIRECTOR/PDMR SHAREHOLDINGa7407v.htm
2022-08-106-K2022-08-10DIRECTOR/PDMR SHAREHOLDINGa6197v.htm
2022-08-036-K2022-08-03CURRENT REPORT OF FOREIGN ISSUERgsk-6k_080222.htm
2022-08-016-K2022-08-01TOTAL VOTING RIGHTSa5255u.htm
2022-08-016-K2022-08-01DIRECTOR/PDMR SHAREHOLDINGa4854u.htm
2022-07-296-K2022-07-29DIRECTOR/PDMR SHAREHOLDINGa3041u.htm
2022-07-296-K2022-07-29GSK BOARD CHANGEa2394u.htm
2022-07-286-K2022-07-28DIRECTOR/PDMR SHAREHOLDINGa1293u.htm
2022-07-276-K2022-07-272ND QUARTER RESULTSa8358t.htm
2022-07-226-K2022-07-22HOLDING(S) IN COMPANYa5090t.htm
2022-07-226-K2022-07-22BOARD AND COMMITTEE CHANGESa5058t.htm
2022-07-186-K2022-07-18COMPLETION OF GSK SHARE CONSOLIDATIONa8881s20.htm
2022-07-186-K2022-07-18HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATIONa7293s.htm
2022-07-126-K2022-07-12DIRECTOR/PDMR SHAREHOLDINGa1642s.htm
2022-07-086-K2022-07-08DIRECTOR/PDMR SHAREHOLDINGa9195r.htm
2022-07-086-K2022-07-08DIRECTOR/PDMR SHAREHOLDINGa9163r.htm
2022-07-086-K2022-07-08DIRECTOR/PDMR SHAREHOLDINGa9019r.htm
2022-07-086-K2022-07-08DIRECTOR/PDMR SHAREHOLDINGa9004r.htm
2022-07-086-K2022-07-08DIRECTOR/PDMR SHAREHOLDINGa8966r.htm
2022-07-066-K2022-07-06RESULT OF GENERAL MEETINGa5786r.htm
2022-07-066-K2022-07-06DIRECTOR/PDMR SHAREHOLDINGa5133r.htm
2022-07-056-K2022-07-05GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022a3934r.htm
2022-07-056-K2022-07-05DIRECTOR/PDMR SHAREHOLDINGa3608r.htm
2022-07-056-K2022-07-05DIRECTOR/PDMR SHAREHOLDINGa3551r.htm
2022-07-016-K2022-07-01TOTAL VOTING RIGHTSa0869r.htm
2022-07-016-K2022-07-01GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGYa0772r.htm
2022-06-286-K2022-06-28DIRECTOR/PDMR SHAREHOLDINGa5409q.htm
2022-06-286-K2022-06-28GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPANa3777q.htm
2022-06-276-K2022-06-27DIRECTOR/PDMR SHAREHOLDINGa3498q.htm
2022-06-246-K2022-06-24DIRECTOR/PDMR SHAREHOLDINGa1811q.htm
2022-06-166-K2022-06-16DIRECTOR/PDMR SHAREHOLDINGa1535p.htm
2022-06-106-K2022-06-10POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINEa4021o.htm
2022-06-096-K2022-06-09DIRECTOR/PDMR SHAREHOLDINGa3782o.htm
2022-06-076-K2022-06-07DIRECTOR/PDMR SHAREHOLDINGa0574o.htm
2022-06-066-K2022-06-06US FDA APPROVAL OF PRIORIXa7059n.htm
2022-06-016-K2022-06-01DEMERGER UPDATE: PUBLICATION OF DOCUMENTSa5914n.htm
2022-06-016-K2022-06-01DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCAa5325n.htm
2022-06-016-K2022-06-016-Kd363577d6k.htm
2022-05-316-K2022-05-31GSK TO ACQUIRE AFFINIVAX, INC.a3651n.htm
2022-05-316-K2022-05-31FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARDa2374n.htm
2022-05-276-K2022-05-26GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPAa9814m.htm
2022-05-256-K2022-05-25DIRECTOR/PDMR SHAREHOLDINGa8176m.htm
2022-05-236-K2022-05-23FORM 6-Kgsk_6k.htm
Advertisement